Director, Medical Science Liaison (Dallas, AR, LA, OK, MS)
Revolution Medicines
Summary
We are seeking a highly motivated and experienced professional to join our team as a Lung Medical Science Liaison. Key aspects of this role will include engage in peer-to-peer scientific dialogue with healthcare professionals that translate into meaningful insights, serve as a therapeutic expert and thought partner to internal teams, liaison between Revolution Medicines and clinical study sites / investigators, and provide support for medical education, advisory boards, and medical congresses.
Job description
Medical Science Liaisons (MSLs) are an essential member of the Medical Affairs team who will work as an extension of the Medical Affairs organization. The Lung MSL team will serve as a key liaison between Revolution Medicines and healthcare professionals. Within an assigned geographic territory, the MSL will be responsible for cultivating and strengthening professional relationships with key opinion leaders (KOLs), healthcare providers, and academic centers of excellence involved in various phases of product development. The individual will collaborate with stakeholders within medical affairs and across the organization, including but not limited to Clinical Development, Commercial, Program Management, Clinical Operations, and Compliance teams. The ideal candidate is an effective communicator, driven, detail-oriented, proactive, and a skilled collaborator. This role covers Dallas, Arkansas, Louisiana, Oklahoma and Mississippi. The candidate should be located within an hour drive of a major airport.
- Develop and maintain strong relationships with KOLs, healthcare professionals, and academic institutions to advance scientific and medical knowledge.
- Communicate clinical and scientific data to KOLs and healthcare professionals through presentations, educational programs, and scientific discussions.
- Support the synthesis and communicate scientific insights from KOLs to relevant internal teams.
- Provide scientific support for medical congresses, advisory boards and other relevant scientific engagements to enhance the visibility of RevMed within the scientific and medical communities.
- Establish credibility as a scientific expert and resource for internal stake holders, providing medical and scientific support for products and therapeutic areas.
- Collaborate cross-functionally with medical affairs, clinical development, marketing and other teams to support the development and execution of medical strategies and tactics.
- Stay current with scientific literature, emerging research, and competitive landscape.
- Adhere to Revolution Medicines Core Values and policies.
- Understand the regulatory requirements for customer engagement by field-based employees.
Requirements
- Doctoral degree in scientific or medical discipline
- 8+ years experience as an MSL or in a similar role within the pharmaceutical or biotech industry
- 3+ years experience as a MSL working in the lung cancer disease state area
- Strong understanding of clinical research methodologies and drug development processes
- Knowledge and experience within the oncology therapeutic area
- Excellent verbal and written communication skills
- Proven ability to analyze and synthesize scientific information effectively
- Excellent presentation skills, with the ability to effectively communicate complex scientific data to diverse audiences
- Strong networking skills with proven ability to successfully build and maintain relationships with KOLs and healthcare professionals
- Self-directed and able to thrive in a fast-paced and dynamic environment
- Willingness to travel up to 60% of time
Benefits
- Competitive cash compensation
- Robust equity awards
- Strong benefits
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.